Novo Nordisk A/S (NYSE:NVO) Receives $144.50 Average Price Target from Analysts

Novo Nordisk A/S (NYSE:NVO) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $144.50.

Several equities analysts recently commented on NVO shares. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets decreased their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently modified their holdings of NVO. Davis R M Inc. purchased a new stake in Novo Nordisk A/S in the first quarter worth approximately $201,000. Vaughan David Investments LLC IL bought a new position in shares of Novo Nordisk A/S during the 1st quarter valued at $227,000. Pitcairn Co. purchased a new position in Novo Nordisk A/S in the 1st quarter worth $1,915,000. Natixis lifted its stake in Novo Nordisk A/S by 748.1% in the first quarter. Natixis now owns 5,903 shares of the company’s stock worth $758,000 after purchasing an additional 5,207 shares during the last quarter. Finally, Crewe Advisors LLC purchased a new stake in Novo Nordisk A/S during the first quarter valued at about $50,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $105.06 on Tuesday. The business’s fifty day moving average is $115.48 and its 200 day moving average is $128.80. The firm has a market cap of $471.46 billion, a price-to-earnings ratio of 34.00, a PEG ratio of 1.32 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.